Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 4-phenylbutyrate
2. 4-phenylbutyric Acid, Calcium Salt
3. 4-phenylbutyric Acid, Sodium Salt
4. Ammonaps
5. Buphenyl
6. Sodium 4-phenylbutanoate
7. Sodium 4-phenylbutyrate
8. Sodium Phenylbutyrate
1. 4-phenylbutanoic Acid
2. 1821-12-1
3. Benzenebutanoic Acid
4. Benzenebutyric Acid
5. Phenylbutyrate
6. Phenylbutyric Acid
7. Gamma-phenylbutyric Acid
8. Omega-phenylbutanoic Acid
9. Butyric Acid, 4-phenyl-
10. 4-phenyl-butanoic Acid
11. 4-phenyl-n-butyric Acid
12. 1-phenylbutyric Acid
13. Gamma-phenyl-butyric Acid
14. 4-phenyl-butyric Acid
15. Omega-phenylbutyric Acid
16. Chebi:41500
17. Phenylbutanoic Acid
18. .gamma.-phenylbutyric Acid
19. Gamma-phenyl-n-butyric Acid
20. Mfcd00004403
21. .omega.-phenylbutanoic Acid
22. 7wy7ybi87e
23. Mls000069408
24. Pba
25. 4-phenylbutyric Acid (4-pba)
26. Nsc-295
27. Smr000059104
28. 4-phenyl Butyric Acid
29. Nsc 295
30. Gamma-phenylbutanoic Acid
31. Ncgc00018113-03
32. Einecs 217-341-8
33. Hdinhib_000004
34. Unii-7wy7ybi87e
35. Benzenebutyrate
36. Benzenebutanoate
37. Ai3-12065
38. G-phenylbutyrate
39. G-phenylbutanoate
40. W-phenylbutanoate
41. G-phenyl-butyrate
42. 4-phenyl-butyrate
43. 2-methyl-1-phenyl-propan-2-amine
44. Gamma-phenylbutyrate
45. G-phenylbutyric Acid
46. Gamma-phenylbutanoate
47. Omega-phenylbutanoate
48. 4-phenyl-n-butyrate
49. G-phenylbutanoic Acid
50. Gamma-phenyl-butyrate
51. W-phenylbutanoic Acid
52. 4-phenylbutyric Acid Sodium 100 Microg/ml In Acetonitrile:water
53. G-phenyl-butyric Acid
54. Spectrum_001331
55. 2ay7
56. 3tz2
57. Opera_id_387
58. Specplus_000814
59. Spectrum2_001798
60. Spectrum3_000782
61. Spectrum4_000092
62. Spectrum5_001003
63. 4-pba;benzenebutyric Acid
64. Bmse000701
65. Epitope Id:167707
66. Ec 217-341-8
67. Schembl1716
68. Chembl1469
69. 3-phenylpropylcarboxylic Acid
70. 4-phenolsulfonic Acid Sodium
71. 4-phenylbutyric Acid, 99%
72. Bspbio_002484
73. Kbiogr_000384
74. Kbioss_001811
75. Mls001076482
76. Divk1c_006910
77. Spbio_001755
78. .gamma.-phenyl-n-butyric Acid
79. Gtpl8480
80. Nsc295
81. Dtxsid2037631
82. Kbio1_001854
83. Kbio2_001811
84. Kbio2_004379
85. Kbio2_006947
86. Kbio3_001704
87. Obkxeaxtfzpchs-uhfffaoysa-
88. Zinc56568
89. Hms2234g14
90. Hms3259m07
91. Bcp10715
92. Cs-d1686
93. Hy-a0281
94. Str05306
95. Bdbm50480960
96. Ccg-39733
97. Cx1106
98. S3592
99. Stl164372
100. Akos000154540
101. Ac-3254
102. Am84635
103. Db06819
104. Nc00469
105. Ps-4322
106. Ncgc00018113-01
107. Ncgc00018113-02
108. Ncgc00018113-04
109. Ncgc00018113-18
110. Nci60_002455
111. Nci60_020145
112. Sy004771
113. Ft-0619401
114. Ft-0673736
115. P0643
116. En300-35719
117. C21793
118. A812651
119. Q-200507
120. Brd-k67102207-001-02-6
121. Brd-k67102207-236-01-0
122. Q27088364
123. F2190-0002
124. 1262970-43-3
| Molecular Weight | 164.20 g/mol |
|---|---|
| Molecular Formula | C10H12O2 |
| XLogP3 | 2.4 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 4 |
| Exact Mass | 164.083729621 g/mol |
| Monoisotopic Mass | 164.083729621 g/mol |
| Topological Polar Surface Area | 37.3 Ų |
| Heavy Atom Count | 12 |
| Formal Charge | 0 |
| Complexity | 137 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Adjunctive therapy for the management of chronic urea cycle disorders due to deficiencies in carbamylphosphate (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase. it is indicated in all neonatal- onset efficiency presenting within the first 28 days of life. Also indicated in patients with late-onset, presenting after the first month of life with a history of hyperammonemic encephalopathy.
FDA Label
Decreases elevated plasma ammonia glutamine levels
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Absorption
Under fasting condition the Cmax of a single orally ingested 5g tablet and 5g powder after 1 hour are respectively 218mcg/ml and 195mcg/ml. The effect of food on phenylbutyrate absorption is still unknown.
Route of Elimination
The major route of elimination is the kidneys as phenylacetylglutamine.
Volume of Distribution
The volume of distribution of phenylbutyrate is 0.2 l/kg.
Clearance
Within 24 hours 80-100% of the administered dose in eliminated in the urine as pheylacetylglutamine.
The overall disposition of sodium phenylbutyrate and its metabolites has not been characterized fully. However, the drug is known to be metabolized to phenylacetate and subsequently to phenylacetylglutamine. Metabolism of phenylbutyrate occurs mainly in liver and kidney.
For sodium phenylbutyrate the half life is 0.77 hours. For phenylacetate the half life is 1.15 hours.
Sodium phenylbutyrate is a pro-drug that is metabolized to the active compound phenylacetate. Phenylacetate conjuages with glutamine via acetylation reaction to form the product phenylacetylglutamine, which is excreted by the kidneys. This provides an alternative mechanism for waste nitrogen excretion.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A 4-Phenyl Butyric Acid manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of 4-Phenyl Butyric Acid, including repackagers and relabelers. The FDA regulates 4-Phenyl Butyric Acid manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. 4-Phenyl Butyric Acid API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of 4-Phenyl Butyric Acid manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A 4-Phenyl Butyric Acid supplier is an individual or a company that provides 4-Phenyl Butyric Acid active pharmaceutical ingredient (API) or 4-Phenyl Butyric Acid finished formulations upon request. The 4-Phenyl Butyric Acid suppliers may include 4-Phenyl Butyric Acid API manufacturers, exporters, distributors and traders.
click here to find a list of 4-Phenyl Butyric Acid suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A 4-Phenyl Butyric Acid DMF (Drug Master File) is a document detailing the whole manufacturing process of 4-Phenyl Butyric Acid active pharmaceutical ingredient (API) in detail. Different forms of 4-Phenyl Butyric Acid DMFs exist exist since differing nations have different regulations, such as 4-Phenyl Butyric Acid USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A 4-Phenyl Butyric Acid DMF submitted to regulatory agencies in the US is known as a USDMF. 4-Phenyl Butyric Acid USDMF includes data on 4-Phenyl Butyric Acid's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The 4-Phenyl Butyric Acid USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of 4-Phenyl Butyric Acid suppliers with USDMF on PharmaCompass.
4-Phenyl Butyric Acid Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of 4-Phenyl Butyric Acid GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right 4-Phenyl Butyric Acid GMP manufacturer or 4-Phenyl Butyric Acid GMP API supplier for your needs.
A 4-Phenyl Butyric Acid CoA (Certificate of Analysis) is a formal document that attests to 4-Phenyl Butyric Acid's compliance with 4-Phenyl Butyric Acid specifications and serves as a tool for batch-level quality control.
4-Phenyl Butyric Acid CoA mostly includes findings from lab analyses of a specific batch. For each 4-Phenyl Butyric Acid CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
4-Phenyl Butyric Acid may be tested according to a variety of international standards, such as European Pharmacopoeia (4-Phenyl Butyric Acid EP), 4-Phenyl Butyric Acid JP (Japanese Pharmacopeia) and the US Pharmacopoeia (4-Phenyl Butyric Acid USP).
LOOKING FOR A SUPPLIER?
